MSTN and/or its downstream targets have been found to be upregulated in many experiments on cancer cachexia (Costelli et al., 2008; Bonetto et al., 2009; Zhou et al., 2010; Murphy et al., 2011; Aversa et al., 2012; Padrão et al., 2013; Chacon-Cabrera et al., 2014; Silva et al., 2015; Chen M. C. et al., 2016; Sun et al., 2016; Chen M. C. et al., 2018; Salazar-Degracia et al., 2018; Lee et al., 2019; Huot et al., 2020), as well as in studies exploring the effect of doxorubicin administration (Kavazis et al., 2014; Liu et al., 2019). This evidence concerns the gene MSTN and cancer.